📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-16 11:16
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
34 announcements match the current filters (relevance ≥ 5).
Q1 FY27 Revenue rises 20% to ₹946 Cr; Net Profit jumps 115% to ₹79 Cr
Viyash Scientific reported strong Q1 FY27 performance following the completion of its integration, with revenue increasing 19.5% YoY to ₹946 crore. EBITDA surged 59.2% YoY to ₹205 crore as EBITDA margins expanded by ~530 bps to 21.6%. Net profit more than doubled, rising 115% YoY to ₹79 crore, absorbing an incremental ESOP cost of ₹19 crore. The balance sheet strengthened significantly with net debt falling to ₹86 crore (Net Debt/EBITDA of 0.1x).
Confidence: HIGH
What changedSubmission of the detailed Q1 FY27 earnings call transcript following post-merger integration and strong quarterly operational execution.
Why it mattersDemonstrates post-merger integration success, margin expansion, substantial deleveraging to near net debt-free status, and inorganic expansion into European companion animal healthcare.
Q1 FY27 Revenue: ₹946 crQ1 FY27 EBITDA: ₹205 crQ1 FY27 PAT: ₹79 crNet Debt: ₹86 crESOP Expense in Q1: ₹19 cr
📅 Short termMarket sentiment should be supported by strong operational results, lower finance costs (₹12.5 cr vs ₹20.4 cr YoY), and healthy US human formulation momentum (+60%).
📈 Long termWith net debt down to 0.1x EBITDA, the company has balance sheet headroom for organic capex in high-potent APIs and CDMO, alongside companion animal expansion in Europe.
⚠ Risk flags
- API revenue timing sensitivity and raw material volatility.
- Execution and closing conditions for the cross-border European acquisition (Bio For Life).
Key Highlights
Revenue from operations grew 19.5% YoY to ₹946 crore with gross margins reaching 54.1%.
Adjusted EBITDA rose 59.2% YoY to ₹205 crore, reflecting an EBITDA margin of 21.6%.
Net profit stood at ₹79 crore (+115% YoY) after accounting for a ₹19 crore non-cash ESOP expense.
Net debt reduced to ₹86 crore, reducing leverage to 0.1x Net Debt/EBITDA compared to ~1x a year earlier.
Signed definitive SPA to acquire Bio For Life in Italy, adding direct access to 85 companion animal products and 85% vet clinic coverage.
👀 What to Watch
Track the closing and integration timeline of the Bio For Life (Italy) acquisition and observe if the 20-22% EBITDA margin trajectory sustains in upcoming quarters.
Viyash Q1 FY27 Revenue up 19.5% to ₹946.4 Cr; EBITDA Margins Expand to 21.6%
Viyash Scientific reported a robust Q1 FY27 with consolidated revenue of ₹946.4 Cr, a 19.5% YoY increase. Profitability saw a significant boost as EBITDA grew 59.2% YoY to ₹204.7 Cr, driven by a 530 bps margin expansion to 21.6%. The company is also expanding its European footprint through the acquisition of Bio For Life in Italy, targeting the companion animal market. Financial health remains strong with Net Debt to EBITDA at a minimal 0.1x.
Confidence: HIGH
What changedThe company has demonstrated significant operational leverage, resulting in a sharp increase in EBITDA margins and a strategic pivot toward the Italian companion animal market via a new acquisition.
Why it mattersThe successful integration of previous acquisitions is now yielding higher profitability and a cleaner balance sheet, providing the financial flexibility to pursue further inorganic growth in specialized segments.
Q1 Revenue: ₹946.4 CrEBITDA Margin: 21.6%YoY EBITDA Growth: 59.2%Net Debt to EBITDA: 0.1xFormulations Growth: 33%
📅 Short termThe stock is likely to react positively to the strong margin expansion and the double-digit revenue growth in the formulations segment.
📈 Long termThe shift towards specialized animal healthcare and complex APIs, combined with a disciplined M&A approach and low leverage, positions the company for structural margin improvement over the coming years.
⚠ Risk flags
- ESOP costs (₹24.6 Cr in Q1) impacting reported PAT
- Integration risks associated with the Italian acquisition
Key Highlights
Consolidated Revenue reached ₹946.4 Cr in Q1 FY27, a 19.5% YoY increase from ₹791.6 Cr.
EBITDA (adjusted for ESOP) rose to ₹204.7 Cr, representing a 59.2% YoY growth.
Operating margins improved significantly by 530 bps YoY to reach 21.6%.
Formulations revenue grew 33% YoY to ₹554.7 Cr, now comprising approximately 58% of total sales.
Net Debt reduced to ₹86.1 Cr, bringing the Net Debt/EBITDA ratio down to 0.1x from 0.2x in Q4 FY26.
👀 What to Watch
Watch for the completion of the Bio For Life acquisition by September 2026 and the subsequent integration of its 85-90 product companion animal portfolio into the global pipeline.
114.9% PAT Growth in Q1 FY27; Viyash Scientific Reports ₹946.4 Cr Revenue
Viyash Scientific reported a robust Q1 FY27 with consolidated revenue rising 19.5% YoY to ₹946.4 crore. Profitability significantly outperformed revenue growth, with PAT surging 114.9% to ₹79.3 crore, supported by EBITDA margin expansion to 21.6% from 16.2% in the previous year. The company maintains a very strong balance sheet with a Net Debt/EBITDA ratio of 0.1x. Additionally, the company is expanding its European footprint through the acquisition of Bio For Life in Italy, targeting the companion animal segment.
Confidence: HIGH
What changedThe company has demonstrated a significant jump in operational efficiency and profitability following its integration efforts, moving from a low-margin phase to a 21.6% EBITDA margin profile.
Why it mattersThe results validate the company's 'integrated platform' strategy and its ability to generate high cash flows while maintaining low debt, providing a strong foundation for its European expansion.
Q1 Revenue: ₹9,464 MillionQ1 PAT: ₹793 MillionEBITDA Margin: 21.6%Net Debt / EBITDA: 0.1xQ1 Revenue vs TTM Revenue: ~97%
📅 Short termThe stock is likely to react positively to the triple-digit PAT growth and significant margin expansion reported for the quarter.
📈 Long termThe structural shift toward the companion animal segment and global distribution (100+ countries) suggests a potential long-term re-rating if high growth and margins are maintained.
⚠ Risk flags
- High P/E ratio (293.8) indicates high market expectations
- Integration risks associated with the Italian acquisition
- Regulatory compliance risks across multiple international manufacturing sites
Key Highlights
Consolidated Revenue increased by 19.5% YoY to ₹9,464 Million (₹946.4 Cr)
EBITDA (excluding ESOP costs) grew by 59.2% to ₹2,047 Million
Net Profit (PAT) surged by 114.9% to ₹793 Million (₹79.3 Cr)
EBITDA margins expanded by 540 basis points to reach 21.6%
Net Debt / EBITDA remains highly conservative at 0.1x
👀 What to Watch
Investors should monitor the integration of the Bio For Life acquisition in Italy and check if the 21%+ EBITDA margins are sustainable in the coming quarters as the company scales its companion animal portfolio.
Viyash to Convert Rs 400 Cr Loan to Equity in Subsidiary; Expands to Vietnam
Viyash Scientific has approved the conversion of a Rs 400.02 Cr intercompany loan into equity for its wholly-owned subsidiary, Alivira Animal Health Limited (AAHL), to strengthen its capital structure and reduce interest costs. The company is also expanding internationally by incorporating a subsidiary in Vietnam with an initial investment of up to USD 400,000. Additionally, the board approved the allotment of 10,30,775 equity shares under its 2026 ESOP scheme at an exercise price of Rs 101 per share. AAHL remains a critical driver for the company, reporting a FY26 turnover of Rs 449.45 Cr, which is approximately 46% of the group's TTM revenue.
Confidence: HIGH
What changedViyash is restructuring the balance sheet of its primary subsidiary by converting debt to equity and initiating a direct presence in the Vietnamese animal health market.
Why it mattersThe loan conversion strengthens the financial health of AAHL, which contributes nearly half of the group's revenue. The Vietnam expansion signals a strategic move to capture growth in the Southeast Asian veterinary market.
Loan Conversion Value: Rs 400.02 CrLoan Conversion vs TTM Revenue: 40.98%AAHL FY26 Turnover: Rs 449.45 CrESOP Exercise Price: Rs 101Vietnam Investment Cap: USD 400,000
📅 Short termThe market is likely to view the balance sheet strengthening of the core subsidiary and the international expansion plans positively over the coming weeks.
📈 Long termThe reduction in interest burden at the subsidiary level and the establishment of a distribution network in Vietnam could provide structural support to consolidated profitability.
⚠ Risk flags
- Execution risk in the new Vietnam market
- Minor equity dilution from ESOP allotments
Key Highlights
Conversion of Rs 400.02 Cr intercompany loan into equity for subsidiary Alivira Animal Health Limited (AAHL)
Allotment of 10,30,775 equity shares under ESOP 2026 at an exercise price of Rs 101 per share
Planned investment of up to USD 400,000 for a new step-down subsidiary in Vietnam
AAHL FY26 turnover grew to Rs 449.45 Cr from Rs 368.14 Cr in FY25
Total paid-up equity capital increased to 43,99,07,588 shares of Rs 2 each
👀 What to Watch
Investors should monitor the impact of the loan conversion on AAHL's interest expenses and consolidated margins in upcoming quarters, alongside the execution of the Vietnam market entry.
Viyash Approves Rs 400 Cr Loan-to-Equity Conversion for Subsidiary and Vietnam Expansion
Viyash Scientific approved a major capital restructuring of its 100% subsidiary, Alivira Animal Health Limited (AAHL), by converting a Rs 400.02 Cr intercompany loan into equity to reduce interest burden. The company also announced its entry into Vietnam with a new step-down subsidiary and an initial investment of up to USD 400,000. Additionally, the board allotted 10.31 lakh equity shares under its 2026 ESOP scheme at Rs 101 per share. These moves follow a period of significant growth for AAHL, which saw its turnover rise to Rs 449.45 Cr in FY26.
Confidence: HIGH
What changedViyash is converting internal debt into equity for its primary animal health subsidiary and establishing a direct commercial presence in Vietnam.
Why it mattersThe debt-to-equity conversion improves the subsidiary's balance sheet health, while the Vietnam expansion opens a new geographic market for its API and veterinary products.
Loan Conversion Value: Rs 400.02 CrLoan vs TTM Revenue: ~41%AAHL FY26 Turnover: Rs 449.45 CrVietnam Investment: USD 400,000ESOP Exercise Price: Rs 101
📅 Short termThe market is likely to view the balance sheet strengthening of the key subsidiary and the international expansion plans as positive developments.
📈 Long termThe restructuring of AAHL and the entry into Vietnam suggest a focus on scaling the animal health business, which could drive structural growth over the next 2-3 years.
⚠ Risk flags
- Execution risk in the new Vietnam market
- Minor equity dilution from ESOP allotments
Key Highlights
Conversion of Rs 400.02 Cr intercompany loan into equity for subsidiary AAHL to strengthen its capital structure.
Planned investment of up to USD 400,000 for the incorporation of a new subsidiary in Vietnam.
Allotment of 10,30,775 equity shares at Rs 101 per share under the ESOP Scheme 2026.
AAHL reported a turnover of Rs 449.45 Cr for FY26, representing approximately 46% of Viyash's TTM consolidated revenue.
Paid-up equity share capital increased from Rs 87.77 Cr to Rs 87.98 Cr following the ESOP allotment.
👀 What to Watch
Investors should monitor the improvement in consolidated net margins resulting from reduced interest expenses at the subsidiary level and track the execution timeline for the Vietnam market entry.
EUR 16.976 Million M&A: Viyash Executes SPA to Acquire BioForLife Italia
Viyash Scientific Limited, through its Irish subsidiary Alivira Animal Health, has executed a definitive Sale and Purchase Agreement (SPA) to acquire 100% of BioForLife Italia s.r.l. for EUR 16.976 million. The deal structure includes an upfront payment of EUR 15.0 million and a deferred consideration of EUR 1.976 million linked to contractual conditions. At current exchange rates, the deal value is approximately Rs 154 crore, representing roughly 15.8% of the company's TTM revenue of Rs 976 crore. The transaction is now pending Italian FDI (Golden Power) clearance.
Confidence: HIGH
What changedThe acquisition of BioForLife Italia has progressed from a proposal (announced June 8, 2026) to a binding Sale and Purchase Agreement with finalized payment terms.
Why it mattersThis acquisition significantly expands Viyash's animal health footprint in Europe via its subsidiary Alivira, contributing to inorganic revenue growth and potentially higher-margin specialty generic exposure.
Total Consideration: EUR 16.976 millionUpfront Payment: EUR 15.0 millionDeferred Consideration: EUR 1.976 millionDeal Value vs TTM Revenue: ~15.8%Target Stake: 100%
📅 Short termThe execution of the definitive agreement is a positive milestone that provides clarity on deal terms and valuation, likely supporting stock sentiment.
📈 Long termIf successfully integrated, this acquisition strengthens the company's global animal health portfolio, though the high P/E of 297.9 indicates the market has already priced in significant growth.
⚠ Risk flags
- Regulatory risk regarding Italian Golden Power clearance
- Integration risk of an international entity
- Achievement of contractual conditions for deferred payment
Key Highlights
Total base consideration fixed at EUR 16.976 million for 100% equity acquisition
Upfront cash payment of EUR 15.0 million to be paid at the time of closing
Deferred consideration of EUR 1.976 million tied to specific contractual-continuation conditions
Deal value represents approximately 15.8% of Viyash's TTM revenue of Rs 976 crore
Completion is subject to Italian FDI / Golden Power regulatory clearance
👀 What to Watch
Investors should monitor the timeline for Italian regulatory approvals and subsequent quarterly results to assess the margin contribution from this European animal health asset.
Viyash Scientific Projects FY26 EBITDA to Reach INR 7,025 MN Following Strategic Merger
Viyash Scientific (formerly Sequent Scientific) outlined its post-merger trajectory, projecting a significant EBITDA increase from INR 2,739 MN in FY24 to INR 7,025 MN by FY26. The company has successfully integrated 16 global manufacturing facilities and an R&D team of over 200 scientists, filing 185+ patents to date. The business model is now diversified across Animal Formulations (45%), API/CDMO (43%), and Human Formulations (12%), leveraging 9 USFDA-approved sites to capture global market trends.
Key Highlights
Projected FY26 revenue of INR 34,203 MN, representing steady growth from INR 26,807 MN in FY24.
EBITDA margins are expected to more than double from FY24 levels, reaching INR 7,025 MN in FY26 due to merger synergies.
Global footprint established with 16 manufacturing sites across India, USA, Spain, Turkey, and Brazil.
Strong R&D pipeline with 60 patents filed since FY23 and 185+ cumulative patents filed.
Q4FY26 demonstrated strong momentum with 19% YoY revenue growth and 64% YoY EBITDA growth.
👀 What to Watch
Investors should focus on the company's execution of its FY26 margin expansion targets and the scaling of its high-margin companion animal and oncology portfolios. The successful integration of Sequent and Viyash assets suggests a strong platform for long-term value creation in the specialized pharma space.
Viyash Scientific to Acquire Italy's BioForLife for ~₹188 Crore to Boost Pet Care Business
Viyash Scientific, through its subsidiary Alivira Animal Health, has signed a binding agreement to acquire a 100% stake in Milan-based BioForLife (BFL) for approximately ₹188 crore. BFL is a prominent Italian pet care company specializing in nutritional complements, pharmaceuticals, and diagnostics, with a distribution network reaching over 80% of veterinary clinics in Italy. The acquisition is expected to close in Q2 FY27 and marks a strategic entry into one of Europe's top five animal health markets. This move aims to capitalize on the high-growth companion animal segment by leveraging BFL's front-end sales team to launch Alivira's product pipeline.
Key Highlights
Acquisition of 100% stake in BioForLife Italia S.r.l. for a cash consideration of ~₹188 crore.
Strategic entry into Italy, one of the five largest animal health markets in Europe.
BioForLife provides access to over 80% of veterinary clinics in Italy through its established sales team.
The transaction is expected to conclude by Q2 FY27, strengthening the global companion animal health portfolio.
Synergies include launching Alivira’s pipeline in Italy and expanding BFL’s range to other global markets.
👀 What to Watch
Investors should view this as a positive strategic expansion into the high-margin companion animal segment; monitor the successful integration and revenue synergies starting from late 2026.
Viyash Scientific to acquire Italy's BioForLife for EUR 16.975 Million
Viyash Scientific's step-down subsidiary, Alivira Animal Health Limited, has entered into a binding agreement to acquire 100% of BioForLife Italia s.r.l. for a total consideration of EUR 16.975 million. BioForLife is a Milan-based distributor of veterinary products for companion animals, reporting a steady revenue increase from EUR 7.1 million in 2023 to EUR 9.0 million in 2025. The acquisition will be funded via cash, with EUR 15.0 million payable at closing and the remainder as deferred consideration, aiming to scale Viyash's presence in the European animal health market.
Key Highlights
Acquisition of 100% stake in BioForLife Italia s.r.l. for an aggregate value of EUR 16.975 million.
Target company revenue showed consistent growth: EUR 7.1m (2023), EUR 8.3m (2024), and EUR 9.0m (2025).
Payment structure includes EUR 15.0 million upfront and EUR 1.975 million as deferred consideration within 12 months.
Strategic move to strengthen the companion animal segment in Italy through an established front-end platform.
Transaction is expected to close within 3 months, subject to Italian Golden Power Law approvals.
👀 What to Watch
Investors should monitor the successful integration of this acquisition as it provides a direct front-end presence in the European companion animal market at a reasonable valuation of approximately 1.88x sales.
Viyash Scientific Proposes ₹4 Crore Incentive for CEO and New Board Appointments
Viyash Scientific Limited has issued a postal ballot notice seeking shareholder approval for key leadership and compensation changes. The company proposes a one-time performance incentive of ₹4,00,00,000 (₹4 Crores) for Mr. Rajaram Narayanan, the Whole-time Director & CEO of Animal Health, to be paid in FY 2026-27. Additionally, the company is seeking the appointment of Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive, Non-Independent Directors. Shareholders can cast their votes via remote e-voting between May 30 and June 28, 2026.
Key Highlights
Proposed one-time performance incentive of ₹4,00,00,000 for Mr. Rajaram Narayanan, CEO - Animal Health.
Appointment of Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive, Non-Independent Directors.
Remote e-voting period set from May 30, 2026, to June 28, 2026, with results by June 30, 2026.
The incentive payment is scheduled for the financial year ending March 31, 2027.
The resolutions follow previous approvals from the 40th AGM and a March 2026 postal ballot.
👀 What to Watch
Investors should assess whether the ₹4 crore performance incentive is justified by the company's recent financial trajectory and the CEO's specific contributions. Monitor the voting results on June 30 to gauge institutional and minority shareholder sentiment regarding executive compensation.
Viyash Scientific Reports Strong FY26 Results with PAT Surging 1,324% to ₹225 Crores
Viyash Scientific Limited (formerly Sequent Scientific) reported a transformative FY26, with annual revenue growing 13.8% to ₹3,420 crores and PAT skyrocketing by 1,324% to ₹225 crores. Q4 FY26 was the strongest quarter in the company's history, with EBITDA surpassing ₹200 crores and margins expanding to 21.7%. The company successfully integrated its operations post-merger, leading to significant operational leverage and a credit rating upgrade to AA-. Management is now focusing on high-margin CDMO opportunities and complex product pipelines for FY27.
Key Highlights
FY26 PAT increased by 1,324% to ₹225 crores compared to ₹16 crores in FY25
Q4 FY26 EBITDA rose 64% YoY to ₹200 crores with a margin of 21.7%
Total FY26 revenue reached ₹3,420 crores, driven by an 18% growth in the formulations segment
External credit rating upgraded to AA- (long-term) and A1+ (short-term) reflecting a deleveraged balance sheet
Animal health API business achieved a ₹400 crore run rate after five years of stagnation
👀 What to Watch
Investors should view this as a successful turnaround story post-merger, with improving margins and a strong pipeline in CDMO and complex generics. Monitor the execution of inorganic growth plans and the ramp-up of the innovator business in FY27.
Viyash Scientific Q4 EBITDA Surges 64% to ₹2,001 Mn; Net Debt/EBITDA Drops to 0.2x
Viyash Scientific reported its strongest quarter ever in Q4 FY26, with revenue growing 19.1% YoY to ₹9,200 million. The company's EBITDA for the quarter jumped 63.8% to ₹2,001 million, driven by merger synergies and improved operating leverage following its integration. For the full year FY26, revenue reached ₹34,203 million with a significant margin expansion of 590 bps to 20.5%. Crucially, the company significantly deleveraged its balance sheet, reducing net debt from ₹4,511 million in FY25 to ₹1,661 million in FY26.
Key Highlights
Q4 FY26 revenue grew 19.1% YoY to ₹9,200 Mn, while full-year FY26 revenue rose 13.8% to ₹34,203 Mn.
EBITDA margins expanded by 590 bps YoY to 21.7% in Q4 and 20.5% for the full year FY26.
Net Debt reduced by approximately 63% to ₹1,661 Mn, bringing the Net Debt to EBITDA ratio down to 0.2x from 1.0x.
Formulations segment led growth with an 18% YoY increase in FY26, driven by strong performance in Europe and Emerging Markets.
Successful merger integration achieved with 6 intermediates now validated in-house to replace external procurement.
👀 What to Watch
Investors should note the sharp margin expansion and successful debt reduction as evidence of strong post-merger synergy realization. The company's transition to a nearly debt-free status and its focus on high-margin formulations make it a strong candidate for long-term growth monitoring.
Viyash Scientific Q4 FY26 PAT Surges 306% to ₹664 Mn; FY26 PAT Jumps 1324%
Viyash Scientific reported its strongest quarter ever in Q4 FY26, with revenues growing 19.1% YoY to ₹9,200 million. The company's full-year FY26 performance was exceptional, with PAT skyrocketing by 1324% to ₹2,246 million, driven by merger synergies and operational integration. EBITDA margins improved significantly to 21.7% in Q4 from 15.8% in the previous year. The balance sheet is now highly deleveraged with a Net Debt/EBITDA ratio of just 0.2x, providing room for future inorganic growth.
Key Highlights
Q4 FY26 EBITDA grew 63.8% YoY to ₹2,001 million with margins expanding to 21.7%
Full-year FY26 PAT reached ₹2,246 million, a massive 1324% increase from ₹158 million in FY25
Annual revenue for FY26 stood at ₹34,203 million, marking a 13.8% growth over the previous fiscal
Net Debt to EBITDA ratio significantly improved to 0.2x, indicating a very strong financial position
Management highlighted successful integration of facilities and is evaluating selective inorganic opportunities
👀 What to Watch
Investors should view this as a strong turnaround story with significant margin expansion and debt reduction. The stock is likely to react positively to the record-breaking quarterly performance and robust growth outlook.
Viyash Scientific FY26 Net Profit Grows 30% to ₹758.7 Million; No Dividend Declared
Viyash Scientific Limited reported a strong financial performance for FY26, with consolidated net profit rising 30% to ₹758.7 million from ₹584.9 million in the previous year (restated). Annual revenue from operations increased by 5.5% to ₹13,820.6 million. The company successfully completed a major amalgamation of several entities, which is reflected in the restated figures. Despite the profit growth, the board has opted not to recommend a dividend for FY26 to conserve resources for future expansion.
Key Highlights
Full-year FY26 Net Profit reached ₹758.7 million, a 30% increase over the restated FY25 profit of ₹584.9 million.
Q4 FY26 revenue stood at ₹3,724.9 million, showing steady growth compared to ₹3,443.2 million in Q4 FY25.
The company achieved a significant turnaround in Q4 FY26 with a profit of ₹358.1 million versus a loss of ₹193.7 million in the same quarter last year.
Board approved the grant of 1,30,98,000 stock options to employees under the ESOP Scheme 2026.
The company successfully integrated multiple entities following the NCLT-sanctioned Composite Scheme of Amalgamation effective December 2025.
👀 What to Watch
Investors should monitor the efficiency gains from the recent large-scale merger and the company's ability to scale its pharmaceutical operations. The decision to skip dividends indicates a focus on aggressive reinvestment and growth.
Viyash Scientific FY26 PAT Rises 29.7% to ₹758.7 Million; No Dividend Declared
Viyash Scientific Limited reported a steady 5.5% growth in standalone revenue from operations, reaching ₹13,820.60 million for the fiscal year ended March 31, 2026. The company's Profit After Tax (PAT) saw a significant jump of 29.7% to ₹758.70 million, up from ₹584.90 million in the previous year. Despite the improved profitability and an EPS increase to ₹1.75, the Board has opted not to recommend a dividend to conserve resources. The results reflect the first full year of operations following the major composite scheme of amalgamation involving multiple entities.
Key Highlights
Standalone Revenue from operations grew 5.5% YoY to ₹13,820.60 million in FY26.
Profit After Tax (PAT) increased by 29.7% to ₹758.70 million compared to ₹584.90 million in FY25.
Earnings Per Share (EPS) improved to ₹1.75 from ₹1.36 in the previous fiscal year.
Board approved the grant of 1,30,98,000 stock options under the ESOP Scheme 2026.
No dividend recommended for FY 2025-26 to conserve cash for business requirements.
👀 What to Watch
Investors should monitor the company's margin expansion post-amalgamation and the utilization of conserved cash for future growth. The significant grant of ESOPs suggests a focus on long-term management alignment.
Viyash Scientific Credit Rating Upgraded to 'IND AA-' with Stable Outlook
India Ratings and Research (Ind-Ra) has upgraded the long-term credit rating of Viyash Scientific Limited to 'IND AA-' from 'IND A'. Simultaneously, the short-term rating has been upgraded to 'IND A1+' from 'IND A1'. The upgrade applies to the company's bank loan facilities totaling INR 350 million. This rating action reflects an improvement in the company's credit profile and financial stability, with the outlook now set as Stable.
Key Highlights
Long-term bank facility rating upgraded from 'IND A' to 'IND AA-'
Short-term rating upgraded from 'IND A1' to 'IND A1+'
Outlook revised to 'Stable' from 'Positive' following the multi-notch upgrade
Rating applies to fund-based working capital limits of INR 350 million with ICICI Bank
👀 What to Watch
The credit rating upgrade is a positive signal indicating reduced credit risk and the potential for lower borrowing costs. Investors should view this as a validation of the company's strengthening balance sheet and operational stability.
Viyash Scientific Gets Credit Rating Upgrade to [ICRA]AA- (Stable) for ₹185 Cr Facilities
ICRA Limited has assigned a long-term rating of [ICRA]AA- with a Stable outlook to Viyash Scientific Limited's working capital facilities totaling ₹185.00 Crores. This new rating marks a significant improvement from the company's previous long-term rating of IND A assigned by India Ratings in January 2025. The upgrade reflects a strengthened credit profile and improved financial stability for the pharmaceutical entity. A higher credit rating typically allows a company to access capital at more competitive interest rates, potentially reducing future finance costs.
Key Highlights
ICRA assigned a new long-term rating of [ICRA]AA- (Stable) for ₹185.00 Crores in fund-based facilities.
The assigned rating is higher than the previous long-term rating of IND A/Positive issued in early 2025.
The rated facilities include ₹150.00 Crores from Kotak Mahindra Bank and ₹35.00 Crores from ICICI Bank.
The 'Stable' outlook indicates ICRA's expectation of steady performance and credit metrics in the medium term.
👀 What to Watch
Investors should take this as a positive indicator of the company's improving financial health and reduced default risk. This upgrade may lead to lower borrowing costs, which could positively impact the company's bottom line over time.
Viyash Scientific Appoints Carlyle Group Nominees to Board and Revises ESOP 2026 Pool
Viyash Scientific Limited has appointed Amit Jain and Abhiroop Jayanthi, both senior leaders from the Carlyle Group, as Non-Executive Directors effective April 22, 2026. This move strengthens the board with significant private equity and healthcare sector expertise, as Carlyle is a major stakeholder. Additionally, the company has revised its ESOP 2026 pool downwards to 1,30,98,000 options from the previously proposed 1,34,75,000 options. These changes indicate a strategic alignment with institutional investors and a slight reduction in potential equity dilution from the employee stock scheme.
Key Highlights
Appointment of Amit Jain (Head of Carlyle India) and Abhiroop Jayanthi (MD, Carlyle) as Non-Executive Directors.
Revision of the ESOP 2026 pool to 1,30,98,000 stock options from the earlier 1,34,75,000 options.
Both new directors bring over 15 years of experience in private equity, healthcare, and life sciences.
The appointments are subject to shareholder approval and are effective from April 22, 2026.
👀 What to Watch
Investors should view the direct board representation by Carlyle Group as a positive signal for governance and strategic growth. Monitor how this leadership change impacts the company's expansion in the life sciences sector.
Viyash Scientific Appoints Carlyle Leaders to Board and Revises ESOP Pool to 1.31 Crore Options
Viyash Scientific Limited has appointed Amit Jain and Abhiroop Jayanthi, both senior representatives from the Carlyle Group, to its Board of Directors as Non-Executive Directors. This strategic move brings significant private equity and industry expertise from a global investment firm to the company's leadership. Additionally, the Board approved a downward revision of the ESOP 2026 pool from 1,34,75,000 to 1,30,98,000 stock options. These appointments are subject to shareholder approval and signify strong institutional oversight and backing.
Key Highlights
Appointment of Amit Jain (Head of Carlyle India) and Abhiroop Jayanthi (MD at Carlyle) as Additional Directors.
Revision of ESOP 2026 pool to 1,30,98,000 options, a reduction of 3,77,000 options from the previous proposal.
New directors bring extensive experience in healthcare, life sciences, and private equity sectors.
Board meeting concluded within approximately one hour (11:30 AM to 12:39 PM) on April 22, 2026.
👀 What to Watch
Investors should view the inclusion of Carlyle leadership as a positive sign for corporate governance and strategic growth. Monitor how this institutional expertise influences future capital allocation and expansion plans.
Viyash Scientific Shareholders Approve MD Appointment and Significant ESOP Grant
Shareholders of Viyash Scientific Limited have approved the appointment of Dr. Haribabu Bodepudi as Managing Director and Group CEO for a two-year term with a 97.32% majority. The company also received approval to grant stock options exceeding 1% of the issued capital to a specific identified employee, supported by 97.31% of votes. Additionally, the appointments of Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy as Whole-time Directors were cleared with over 98% favor. These results ensure management stability and provide tools for key personnel retention following the company's rebranding.
Key Highlights
Dr. Haribabu Bodepudi confirmed as MD & Group CEO for 2 years with 97.32% votes in favor
Special resolution passed to grant ESOPs exceeding 1% of issued capital to a single employee
Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy appointed as Whole-time Directors with 98.83% and 98.64% support respectively
Total voting turnout ranged between 74.8% and 79.3% of outstanding shares across different resolutions
👀 What to Watch
Investors should take confidence in the high level of shareholder support for the new leadership team. Monitor the company's operational performance under the newly confirmed CEO to validate the long-term growth strategy.
